To sum up, the MR analysis indicates a potential cause-and-effect connection between KCNJ11 and DPP4 inhibitors and COPD risk, recommending that clinical trials should be conducted to investigate whether antidiabetic drugs offer protective benefits against COPD. Here, DPP4 is linked to chronic obstructive pulmonary disease.